Cetera Investment Advisers
NVO

Cetera Investment Advisers’s Novo Nordisk NVO Stock Holding History

Cetera Investment Advisers’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3M Sell
382,507
-14,050
-4% -$604K 0.02% 806
2026
Q1 		$14.6M Buy
396,557
+110,186
+38% +$5.22M 0.02% 845
2025
Q4 		$14.6M Sell
286,371
-44,247
-13% -$2.26M 0.02% 820
2025
Q3 		$18.3M Buy
330,618
+62,904
+23% +$3.68M 0.02% 678
2025
Q2 		$18.5M Sell
267,714
-28,937
-10% -$1.97M 0.03% 549
2025
Q1 		$20.6M Buy
296,651
+46,169
+18% +$3.81M 0.04% 456
2024
Q4 		$21.5M Sell
250,482
-36,846
-13% -$3.98M 0.05% 401
2024
Q3 		$34.2M Sell
287,328
-3,517
-1% -$469K 0.07% 265
2024
Q2 		$41.5M Buy
290,845
+25,307
+10% +$3.35M 0.1% 207
2024
Q1 		$34.1M Buy
265,538
+217,545
+453% +$25.9M 0.08% 252
2023
Q4 		$4.96M Buy
47,993
+2,693
+6% +$266K 0.04% 435
2023
Q3 		$4.12M Buy
45,300
+1,678
+4% +$148K 0.04% 478
2023
Q2 		$3.53M Buy
43,622
+1,872
+4% +$153K 0.03% 535
2023
Q1 		$3.32M Sell
41,750
-840
-2% -$59.6K 0.03% 529
2022
Q4 		$2.88M Buy
42,590
+14,290
+50% +$838K 0.03% 569
2022
Q3 		$1.41M Sell
28,300
-4,668
-14% -$250K 0.03% 583
2022
Q2 		$1.84M Buy
32,968
+7,256
+28% +$403K 0.03% 566
2022
Q1 		$1.43M Sell
25,712
-866
-3% -$44.4K 0.02% 687
2021
Q4 		$1.49M Buy
26,578
+564
+2% +$30.6K 0.02% 654
2021
Q3 		$1.25M Buy
26,014
+2,988
+13% +$144K 0.02% 695
2021
Q2 		$964K Buy
23,026
+2,082
+10% +$80.7K 0.02% 791
2021
Q1 		$706K Sell
20,944
-3,686
-15% -$131K 0.01% 810
2020
Q4 		$860K Buy
24,630
+12,596
+105% +$435K 0.02% 726
2020
Q3 		$418K Buy
12,034
+5,334
+80% +$178K 0.03% 419
2020
Q2 		$219K Sell
6,700
-10,608
-61% -$339K 0.02% 557
2020
Q1 		$521K Sell
17,308
-426
-2% -$12.7K 0.06% 295
2019
Q4 		$514K Buy
17,734
+1,088
+7% +$30.1K 0.05% 336
2019
Q3 		$431K Buy
16,646
+4,836
+41% +$122K 0.05% 331
2019
Q2 		$300K Sell
11,810
-696
-6% -$17.2K 0.04% 385
2019
Q1 		$326K Sell
12,506
-270
-2% -$6.64K 0.05% 361
2018
Q4 		$295K Buy
12,776
+1,458
+13% +$32.4K 0.05% 342
2018
Q3 		$268K Buy
+11,318
New +$276K 0.04% 393

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Cetera Investment Advisers's NVO Position: Q2 2026 in Review

Cetera Investment Advisers reduced its Novo Nordisk (NVO) stake by 3.5% in Q2 2026, selling an estimated $604K and leaving 382,507 shares worth $18.3M. The position accounts for 0.02% of the portfolio, ranked #806.

Cetera Investment Advisers first reported a position in NVO in Q3 2018 and has held it in 32 quarters since. The position peaked at $41.5M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Cetera Investment Advisers held 382,507 shares of Novo Nordisk worth $18.3M as of Q2 2026.
  • Cetera Investment Advisers sold 14,050 Novo Nordisk shares in Q2 2026, an estimated $604K.
  • Novo Nordisk made up 0.02% of Cetera Investment Advisers's portfolio in Q2 2026, its #806 holding.
  • Cetera Investment Advisers first reported a position in Novo Nordisk in Q3 2018 and has held it in 32 quarters since.
  • Cetera Investment Advisers's Novo Nordisk position peaked at $41.5M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.